UBX Stock Summary and Trading Ideas (Unity Biotechnology | NASDAQ:UBX)

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone which is produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Unity Biotechnology trades on the NASDAQ stock market under the symbol UBX.

As of April 4, 2025, UBX stock price declined to $0.90 with 208,353 million shares trading.

UBX has a beta of 1.26, meaning it tends to be more sensitive to market movements. UBX has a correlation of 0.06 to the broad based SPY ETF.

UBX has a market cap of $15.18 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, UBX traded as high as $18.50 and as low as $.88.

The top ETF exchange traded funds that UBX belongs to (by Net Assets): VTI, VXF, DFAS.

UBX has underperformed the market in the last year with a price return of -42.7% while the SPY ETF was flat at -0.1%. UBX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -29.7% and -50.7%, respectively, while the SPY returned -14.4% and -10.4%, respectively.

UBX support price is $.92 and resistance is $1.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that UBX shares will trade within this expected range on the day.